Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 126 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: clindamycin phosphate Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris

NCT02616614
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Onexton, Clindamycin/benzoyl peroxide gel, Placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
862 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
17
States / cities
Phoenix, Arizona • Chula Vista, California • La Mesa, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Phase 4 Interventional Results available

Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy

NCT04502095
View directory record Official record
Conditions
Bladder Carcinoma, Refractory Bladder Carcinoma, Urinary Tract Infection
Interventions
Clindamycin, Diary, Ertapenem, Levofloxacin, Nitrofurantoin, Trimethoprim-Sulfamethoxazole
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 27, 2026, 5:17 PM EDT
Not listed Phase 4 Interventional

Efficacy of Oral vs IV Antibiotics in the Treatment of Orofacial Osteomyelitis

NCT05867654
View directory record Official record
Conditions
Osteomyelitis of Jaw
Interventions
Amoxicillin-clavulanate 875mg/125mg q12hrs, oral clindamycin 300mg q6hrs, Levofloxacin 750mg QID
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Phase 4 Interventional Results available

Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications

NCT00926367
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin and benzoyl peroxide, benzoyl peroxide 2.5% and adapalene 0.1% gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 27, 2026, 5:17 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Antibiotic Irrigations for Intra-Abdominal Drains

NCT03476941
View directory record Official record
Conditions
Abdominal Abscess
Interventions
Gentamicin Sulfate Inj 20mg/2ml vial for injection, Clindamycin phosphate 6 mg/1ml for injection, Placebo
Drug · Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Phase 4 Interventional

The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery

NCT01912651
View directory record Official record
Conditions
Facial Defect
Interventions
cephalexin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 27, 2026, 5:17 PM EDT
Enrolling by invitation Phase 3 Interventional

Antibiotic Prophylaxis in Rhinoplasty

NCT04194216
View directory record Official record
Conditions
Nasal Obstruction, Nasal Surgical Procedures
Interventions
Intra-operative single intravenous(iv) dose of "cephalexin" 2 g or "clindamycin" 900 mg., Intra-operative single dose (iv) of "cephalexin" 2 g or "clindamycin" 900 mg and postoperative oral dose of "cephalexin" 250mg (every 4 hours) or "clindamycin" 150mg(every 6 hours) for 3 days
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 27, 2026, 5:17 PM EDT
Not listed Phase 4 Interventional

Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris

NCT01448733
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
Drug
Lead sponsor
Zeichner, Joshua, M.D.
Individual
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea

NCT00823901
View directory record Official record
Conditions
Rosacea
Interventions
Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel, Placebo gel
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Not applicable Interventional Results available

Multifactorial Approach to Emergent Cerclage

NCT01114516
View directory record Official record
Conditions
Cervical Insufficiency
Interventions
Indomethacin and antibiotics (cefazolin or clindamycin)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 7, 2014 · Synced Oct 27, 2026, 5:17 PM EDT
Recruiting Phase 4 Interventional

Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

NCT06494072
View directory record Official record
Conditions
Community Acquired Pneumonia in Children
Interventions
Ampicillin for Injection, Ceftriaxone for Injection, Amoxicillin, Ampicillin / Sulbactam Injection, Amoxicillin-clavulanate, Clindamycin, Cefprozil, Levofloxacin
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Months to 18 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications

NCT00964366
View directory record Official record
Conditions
Acne Vulgaris
Interventions
clindamycin and benzoyl peroxide, Dapsone gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne

NCT00964223
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin and benzoyl peroxide gel (Duac® Topical Gel), benzoyl peroxide and adapalene gel (EPIDUO™ Gel)
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Rockville, Maryland • Warren, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris

NCT03522441
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin 1% Gel, Placebo
Drug
Lead sponsor
Akorn, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Encino, California • Sherman Oaks, California • Brandon, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 27, 2026, 5:17 PM EDT
Terminated Not applicable Interventional Results available

Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections

NCT01619410
View directory record Official record
Conditions
Skin Diseases, Bacterial, Abscess
Interventions
Linezolid, Clindamycin
Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Not applicable Interventional Results available

Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection

NCT01235546
View directory record Official record
Conditions
Endometritis, Wound Infection, Abscess, Surgical Site Infection
Interventions
Azithromycin and standard of care, Placebo and standard of care
Drug
Lead sponsor
Alan Tita
Other
Eligibility
14 Years and older · Female only
Enrollment
2,013 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Jackson, Mississippi + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile

NCT01744730
View directory record Official record
Conditions
Bacterial Infections, Obesity
Interventions
Clindamycin
Drug
Lead sponsor
Phillip Brian Smith
Other
Eligibility
2 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Chicago, Illinois • Kansas City, Kansas • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 27, 2026, 5:17 PM EDT
Recruiting Phase 4 Interventional

NextGen - Clinical Implication of Next Generation Sequencing

NCT05206500
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Antibiotic, Next Gen
Drug · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 27, 2026, 5:17 PM EDT
Terminated Phase 4 Interventional

Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens

NCT03560232
View directory record Official record
Conditions
Open Fracture, Post-Op Wound Infection
Interventions
Ceftriaxone, Ampicillin/sulbactam, Piperacillin/tazobactam, Cefazolin + Gentamicin, Clindamycin + Gentamicin
Drug
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Warren, Ohio • Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 27, 2026, 5:17 PM EDT
Active, not recruiting Early Phase 1 Interventional

Experience With Topical Acne Treatment

NCT05582434
View directory record Official record
Conditions
Acne
Interventions
clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel, adapalene 0.3%/BPO 2.5% gel and compounded clindamycin phosphate 1.2% gel, Compounded BPO 2.5% gel, adapalene 0.1% gel, and compounded clindamycin phosphate 1.2% gel
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 85 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Not applicable Interventional

Surgical Site Infection and Antibiotic Use Study

NCT04631185
View directory record Official record
Conditions
Surgical Site Infection, Breast Reconstruction, Antibiotic Use
Interventions
Single pre-operative dose of intravenous antibiotics with intraoperative redosing, One week of post-operative antibiotics
Drug
Lead sponsor
The Plastic Surgery Foundation
Other
Eligibility
18 Years and older · Female only
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections

NCT00711802
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
Daptomycin, Standard of Care (SOC)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
1 Year to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
22
States / cities
Birmingham, Alabama • Oakland, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 27, 2026, 5:17 PM EDT
Completed Phase 3 Interventional Results available

Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne

NCT00776919
View directory record Official record
Conditions
Acne Vulgaris
Interventions
clindamycin / benzoyl peroxide gel, clindamycin gel, BPO gel, vehicle gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years to 45 Years
Enrollment
1,315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
San Diego, California • Santa Monica, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 27, 2026, 5:17 PM EDT
Recruiting Phase 4 Interventional

Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo

NCT07524946
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Bryant, Arkansas • Rogers, Arkansas • Freemont, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 27, 2026, 5:17 PM EDT